Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Nebraska, NE
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Nebraska, NE
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Nevada, NV
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Nevada, NV
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in New Hampshire, NH
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in New Hampshire, NH
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in New Jersey, NJ
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in New Jersey, NJ
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in New York, NY
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in New York, NY
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in North Carolina, NC
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in North Carolina, NC
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Ohio, OH
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Ohio, OH
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Oklahoma, OK
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Oklahoma, OK
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Oregon, OR
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Oregon, OR
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Pennsylvania, PA
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Pennsylvania, PA
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Rhode Island, RI
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Rhode Island, RI
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in South Carolina, SC
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in South Carolina, SC
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Tennessee, TN
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Tennessee, TN
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Texas, TX
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Texas, TX
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Utah, UT
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Utah, UT
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Vermont, VT
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Vermont, VT
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Virginia, VA
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Virginia, VA
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in West Virginia, WV
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in West Virginia, WV
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Wisconsin, WI
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Wisconsin, WI
Click here to add this to my saved trials
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated:  12/1/2016
ALTANA Pharma
mi
from
Cities in Canada,
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease. A 52-week, Multicenter, Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo.
Status: Enrolling
Updated: 12/1/2016
ALTANA Pharma
mi
from
Cities in Canada,
Click here to add this to my saved trials
Chlorhexidine & Pneumonia in Nursing Home Residents
Effect of Topical Oral Chlorhexidine in Reducing Pneumonia in Nursing Home Residents
Status: Enrolling
Updated:  12/1/2016
University of Louisville
mi
from
Louisville, KY
Chlorhexidine & Pneumonia in Nursing Home Residents
Effect of Topical Oral Chlorhexidine in Reducing Pneumonia in Nursing Home Residents
Status: Enrolling
Updated: 12/1/2016
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Echinacea and Acute Respiratory Illness
Efficacy of Ingesting Gaia Herb's Quick Defense Product in Reducing Acute Respiratory Illness Symptomatology in Women: a 12-Week, Double Blind, Placebo-Controlled Randomized Trial
Status: Enrolling
Updated:  12/12/2016
ASU-NCRC Human Performance Lab
mi
from
Kannapolis, NC
Echinacea and Acute Respiratory Illness
Efficacy of Ingesting Gaia Herb's Quick Defense Product in Reducing Acute Respiratory Illness Symptomatology in Women: a 12-Week, Double Blind, Placebo-Controlled Randomized Trial
Status: Enrolling
Updated: 12/12/2016
ASU-NCRC Human Performance Lab
mi
from
Kannapolis, NC
Click here to add this to my saved trials
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/14/2016
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/14/2016
VA Healthcare System
mi
from
Boston, MA
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)
BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/14/2016
VA Healthcare System
mi
from
Boston, MA
Click here to add this to my saved trials
Stylet vs No Stylet During EBUS TBNA
Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)
Status: Enrolling
Updated:  12/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Stylet vs No Stylet During EBUS TBNA
Stylet Versus no Stylet in Endobronchial Ultrasound Transbronchial Aspiration (EBUS-TBNA)
Status: Enrolling
Updated: 12/14/2016
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Status: Enrolling
Updated:  12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Inhaled Iloprost, Dynamic Hyperinflation, and Oxidative Stress in COPD Patients
Status: Enrolling
Updated: 12/15/2016
Lsu Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
New Haven, CT
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Iowa City, IA
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
Clinical Research Facility
mi
from
Galveston, TX
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
Clinical Research Facility
mi
from
Galveston, TX
Click here to add this to my saved trials
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  12/19/2016
mi
from
Calgary,
A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
A Multicenter Longitudinal Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 12/19/2016
mi
from
Calgary,
Click here to add this to my saved trials
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated:  12/20/2016
Center for Immunization Research, JHU
mi
from
Baltimore, MD
Safety and Immune Response to a Live-Attenuated Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children
A Phase I Study of the Safety and Immunogenicity of a Single Dose of the Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine RSV LID ΔM2-2, Lot RSV#007A, Delivered as Nose Drops to RSV-Seronegative Infants and Children 6 to 24 Months of Age
Status: Enrolling
Updated: 12/20/2016
Center for Immunization Research, JHU
mi
from
Baltimore, MD
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Birmingham, AL
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Denver, CO
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Iowa City, IA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Iowa City, IA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Oaks, PA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Oaks, PA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated:  12/20/2016
GSK Investigational Site
mi
from
Frankfurt,
Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
A Two Part, Phase IIa, Randomized, Placebo-controlled Study To Investigate The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin (GSK1325756) in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations
Status: Enrolling
Updated: 12/20/2016
GSK Investigational Site
mi
from
Frankfurt,
Click here to add this to my saved trials
Stress Management Program for World Trade Center (WTC) Responders
Mind-Body Treatment for WTC Responders With Comorbid PTSD and Respiratory Illness
Status: Enrolling
Updated:  12/21/2016
Stony Brook University, Putnam Hall
mi
from
Stony Brook, NY
Stress Management Program for World Trade Center (WTC) Responders
Mind-Body Treatment for WTC Responders With Comorbid PTSD and Respiratory Illness
Status: Enrolling
Updated: 12/21/2016
Stony Brook University, Putnam Hall
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Dimethyl Fumarate for Obstructive Sleep Apnea
A Randomized Clinical Trial of Dimethyl Fumarate as a Novel Therapeutic Agent for Obstructive Sleep Apnea
Status: Enrolling
Updated:  12/27/2016
University of Michigan
mi
from
Ann Arbor, MI
Dimethyl Fumarate for Obstructive Sleep Apnea
A Randomized Clinical Trial of Dimethyl Fumarate as a Novel Therapeutic Agent for Obstructive Sleep Apnea
Status: Enrolling
Updated: 12/27/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Functional Applications of Hyperpolarized 129Xe MRI
Functional Applications of Hyperpolarized 129Xe MRI
Status: Enrolling
Updated:  12/28/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Functional Applications of Hyperpolarized 129Xe MRI
Functional Applications of Hyperpolarized 129Xe MRI
Status: Enrolling
Updated: 12/28/2016
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding
Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding
Status: Enrolling
Updated:  1/5/2017
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding
Topical Microporous Polysaccharide Hemospheres Versus Electrocautery for Control of Pediatric Post-Tonsillectomy Bleeding
Status: Enrolling
Updated: 1/5/2017
Massachusetts Eye & Ear Infirmary
mi
from
Boston, MA
Click here to add this to my saved trials
Interactions Between Intravenous (IV) Cocaine and Lofexidine
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine
Status: Enrolling
Updated:  1/10/2017
California Pacific Medical Center Research Institute
mi
from
San Francisco, CA
Interactions Between Intravenous (IV) Cocaine and Lofexidine
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine
Status: Enrolling
Updated: 1/10/2017
California Pacific Medical Center Research Institute
mi
from
San Francisco, CA
Click here to add this to my saved trials
Interactions Between Intravenous (IV) Cocaine and Lofexidine
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine
Status: Enrolling
Updated:  1/10/2017
Baylor College of Medicine
mi
from
Houston, TX
Interactions Between Intravenous (IV) Cocaine and Lofexidine
Phase 1, Double-Blind, Placebo-Controlled Assessment of Potential Interactions Between Intravenous Cocaine and Lofexidine
Status: Enrolling
Updated: 1/10/2017
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials